MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
477.60
+14.18
+3.06%
After Hours: 470.50 -7.1 -1.49% 18:59 02/06 EST
OPEN
475.69
PREV CLOSE
463.42
HIGH
482.88
LOW
465.20
VOLUME
338.62K
TURNOVER
--
52 WEEK HIGH
615.00
52 WEEK LOW
265.00
MARKET CAP
10.85B
P/E (TTM)
-36.7187
1D
5D
1M
3M
1Y
5Y
1D
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Move
Simply Wall St · 10h ago
Madrigal Equity Grants Signal Hiring Push And Undervalued Share Opportunity
Simply Wall St · 2d ago
Madrigal Pharmaceuticals Grants Equity Awards to New Employees
Reuters · 2d ago
BRIEF-Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Reuters · 2d ago
Does Madrigal Pharmaceuticals (MDGL) Offer Value After Recent Share Price Weakness
Simply Wall St · 3d ago
Sagimet a new buy at Guggenheim on promise of MASH, acne asset
Seeking Alpha · 4d ago
Analysts Conflicted on These Healthcare Names: CVS Health (CVS), Madrigal Pharmaceuticals (MDGL) and Xenon (XENE)
TipRanks · 4d ago
MADRIGAL PHARMACEUTICALS INC <MDGL.O>: BOFA GLOBAL RESEARCH CUTS PRICE OBJECTIVE TO $570 FROM $595
Reuters · 4d ago
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.